Circulating levels of VEGF family and their receptors in hepatocellular carcinoma

Bratislava Medical Journal

Volumn 111, Issue 9, 2010, Pages 485-488

  Kemik, O ^a   Sumer, A ^a   Sarbay Kemik, A ^b   Purisa, S ^c   Tuzun, S ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Haseki Training and Research Hospital   (Turkey)

Author keywords

Angiogenesis; Clinic pathological features; Hepatocellular carcinoma; Metastases; Vascular endothelial growth factor

Indexed keywords

TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77957956751     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Int J Cancer 2001; 94(2): 153-156.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: world-wide incidence and trends. Gastroenterology 2004; 127(5 Suppl 1): S5-S16.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35(3): 519-524.
4. Hormbrey E, Gillespie P, Turner K, Han C; Roberts A, McGrouther D, Harris AL. A critical review of vascular endothelial growth factor analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651-663.
5. Otrock ZK, Makarem JA, Shamseddine Al. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258-268.
6. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor inhibition a critical review. Anticancer Agents Med Chem 2007; 7:223-245.
7. Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res 2007; 27: 3245-3250.
8. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005; 8: 155-163.
9. Ding S, Lin S, Dong X, Yang X, Qu H, Huang S, Liu W, Zhou L, Liu D. Potential prognostic value of circulating levels of VEGF-A in patients with gastric cancer. In Vivo 2005; 19: 793-795.
10. Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, Kondoh K, Watanabe M, Terada H, Nakamura S. The significance of circulating VEGF protein in gastric cancer. Cancer Lett 2003; 192: 215-225.
11. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RL. VEGF-A, -C, and -D in colorectal cancer progression. Neoplasia 2001; 3: 420-427.
12. Wang TB, Deng MH, Qui WS, Dong WG. Association of serum VEGF-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13: 1794-1797; discussion 1797-1798.
13. Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30: 633-637.
14. Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007; 27: 3481-3487.
15. Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G, Rocci L, Rosaria VM, Gebbia N, Tonini G. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximabplus irinotecan. Pharmacogenomics 2007; 8:319-327
16. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney IA, Rizivi A, Ganguly SS. Meausrement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and VE-GFR-2 in gastric adenocarcmoma. World J Gastroenterol 2008; 14 (24):3879-3883.
17. Poreba M, Jazwiec B, Kulickowski K, Poreba R. Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas. Pol Arch Med Wewn 2005; 113: 27-34.
18. Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbaska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia, Eur Cytokine Netw 2003; 14: 149-153.
19. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M. VEGF-D and its receptor VE-GFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-240.
20. Jacobsen J Grankvist K, Rasmuson T, Ljungberg B. Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 2002; 11: 245-252.